Search hospitals > Minnesota > Fergus Falls

Lake Region Healthcare Corporation-Cancer Care

Claim this profile
Fergus Falls, Minnesota 56537
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
131 reported clinical trials
2 medical researchers
Photo of Lake Region Healthcare Corporation-Cancer Care in Fergus FallsPhoto of Lake Region Healthcare Corporation-Cancer Care in Fergus Falls

Summary

Lake Region Healthcare Corporation-Cancer Care is a medical facility located in Fergus Falls, Minnesota. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Lake Region Healthcare Corporation-Cancer Care is involved with conducting 131 clinical trials across 320 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.

Area of expertise

1Cancer
Global Leader
Lake Region Healthcare Corporation-Cancer Care has run 51 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Lake Region Healthcare Corporation-Cancer Care has run 25 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Lake Region Healthcare Corporation-Cancer Care

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Carcinoma
Bladder Cancer
Cancer
Cutaneous Melanoma
Melanoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Chemotherapy Reduction After Surgery

for Breast Cancer

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Lake Region Healthcare Corporation-Cancer Care?
Lake Region Healthcare Corporation-Cancer Care is a medical facility located in Fergus Falls, Minnesota. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Lake Region Healthcare Corporation-Cancer Care is involved with conducting 131 clinical trials across 320 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.